Jefferies analyst Brian Tanquilut maintains $Quest Diagnostics (DGX.US)$ with a buy rating, and adjusts the target price from $160 to $175.
According to TipRanks data, the analyst has a success rate of 49.5% and a total average return of 2.8% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Quest Diagnostics (DGX.US)$'s main analysts recently are as follows:
The revision of the guidance for Quest Diagnostics has been attributed mainly to the integration of LifeLabs and sustained elevated utilization trends. The defensive characteristics of Quest, especially in the context of an election cycle, along with more secure estimates for the coming years, keep the outlook positive.
Quest Diagnostics delivered a strong third-quarter performance, evidenced by exceeding expectations. The company managed to maintain its earnings forecast despite the challenges posed by hurricanes, and provided an optimistic preliminary outlook for fiscal 2025.
The firm has improved its estimates following Quest Diagnostics' strong third-quarter results and encouraging initial outlook for 2025. The company's earnings visibility continues to be robust, supported by stable underlying healthcare utilization trends, gains in market share, and a favorable mix.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
富瑞集团分析师Brian Tanquilut维持$奎斯特诊疗 (DGX.US)$买入评级，并将目标价从160美元上调至175美元。
根据TipRanks数据显示，该分析师近一年总胜率为49.5%，总平均回报率为2.8%。
此外，综合报道，$奎斯特诊疗 (DGX.US)$近期主要分析师观点如下：
Quest Diagnostics指南的修订主要归因于LifeLabs的整合和利用率持续提高的趋势。Quest的防御特征，尤其是在选举周期的背景下，以及对未来几年的更安全的估计，使前景保持乐观。
Quest Diagnostics在第三季度表现强劲，超出预期即为明证。尽管面临飓风带来的挑战，该公司仍设法维持了其收益预期，并对2025财年提供了乐观的初步展望。
在Quest Diagnostics公布强劲的第三季度业绩以及令人鼓舞的2025年初步展望之后，该公司提高了预期。在稳定的基础医疗保健利用率趋势、市场份额的增加和有利的组合的支持下，该公司的盈利知名度继续保持强劲。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
